Clovis Oncology Inc (NASDAQ:CLVS)
| 5.59 Delayed Data As of Oct 23 |  -0.04 / -0.71%Today’s Change | 2.93 Today|||52-Week Range 17.37 | -46.43% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $528.8M |
Company Description
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
Contact Information
Clovis Oncology, Inc. 5500 Flatiron Parkway Boulder Colorado 80301 |
Employees
Shareholders
| Individual stakeholders | 5.12% |
| Mutual fund holders | 28.18% |
| Other institutional | 24.81% |
Top Executives
| Patrick J. Mahaffy | President, Chief Executive Officer & Director |
| Daniel W. Muehl | Chief Financial Officer & Executive Vice President |
| Lindsey Rolfe | Chief Medical Officer & Executive VP-Clinical |
| Paul Edward Gross | Secretary, Chief Compliance Officer & Executive VP |
| Gillian C. Ivers-Read | Chief Regulatory Officer & Executive VP |
